Skip to main content
. 2019 Mar 7;25(9):1142–1157. doi: 10.3748/wjg.v25.i9.1142

Table 11.

Individual studies included for maintenance of clinical remission in ulcerative colitis

Study Country Intervention Comparator Study design Follow-up n Maintenance of clinical remission
Sood et al[32] India AZA - Retrospective cohort 12 mo 111 91%1
AZA - Retrospective cohort 24 mo N/A 88%1
AZA - Retrospective cohort 36 mo N/A 76%1
AZA - Retrospective cohort 48 mo N/A 53%1
AZA - Retrospective cohort 60 mo N/A 38%1
Campbell et al[35] United Kingdom Cyclosporine - Retrospective cohort 1 yr 76 35%2
Cyclosporine - Retrospective cohort 3 yr N/A 10%2
Arts et al[36] Belgium Cyclosporine - Retrospective cohort 1 yr 34 27.8%3
Cyclosporine - Retrospective cohort 3 yr 5 50%3
Hyde et al[44] United Kingdom Cyclosporine - Retrospective cohort 19 mo 50 40%4
Meyers et al[42] United States ACTH Hydrocortisone RCT 1 yr 66 37.5% (ACTH); 23.5% (hydrocortisone)5
1

Remission was defined as absence of symptoms of active disease as rectal bleeding and normal bowel frequency and hence no need for steroids for at least 6 mo;

2

Maintenance of remission defined as absent of disease relapse;

3

The study does not present the exact definition considered for clinical remission;

4

Remission defined as bowel frequency less than three stools per day, no visible blood, no fever or pain;

5

Therapeutic success was considered as a clinical remission, defined by the absence of all symptoms and the reduction of the frequency of bowel movements to two or less per day. ACTH: Adrenocorticotrophic hormone; AZA: Azathioprine; n: Number of patients; N/A: Not available; RCT: Randomized clinical trial.